Michael W. Lutz - Concepedia

Author

Michael W. Lutz

Also Known As

Hongliang Liu, Jeffrey N. Browndyke, Lutz, M, Lutz, Michael, Lutz, Michael W, Lutz,Michael, M Lutz, M Lütz, M W Lutz, M. Lutz

301

Publications

5.7K

Citations

H-Index

162

Concepts

All Affiliations

Duke University Duke Medical Center Duke University Hospital Research Triangle Park Foundation Discovery Institute

About

Michael W. Lutz is an author at Duke University specializing in medicine, alzheimer's disease, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	28	1.6K
2	Engineering	10	10	616
3	Health Sciences	4	4	142
4	Education	3	3	82
5	Management	1	1	53

Michael W. Lutz

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease Allen D. Roses, Michael W. Lutz, Heather Amrine‐Madsen, The Pharmacogenomics Journal	2009	388
The Cubic Ternary Complex Receptor-Occupancy Model III. Resurrecting Efficacy Jack M. Weiss, Paul H. Morgan, Michael W. Lutz, Journal of Theoretical Biology Functional SelectivityMedicineMechanism Of ActionReceptor (Biochemistry)Pharmacotherapy	1996	210
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesics Paul L. Feldman, Marcus F. Brackeen, Joanne Bilotta, Journal of Medicinal Chemistry	1991	203
Novel loci and pathways significantly associated with longevity Yi Zeng, Chao Nie, Junxia Min, Scientific Reports	2016	202
The Cubic Ternary Complex Receptor–Occupancy Model I. Model Description Jack M. Weiss, Paul H. Morgan, Michael W. Lutz, Journal of Theoretical Biology EngineeringModel DescriptionReceptor (Biochemistry)Biomedical ModelingMolecular Modeling	1996	196
A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing Gail Davies, Sarah E. Harris, Chandra A. Reynolds, Molecular Psychiatry Genome-wide Association StudyCognitive ScienceAlzheimer's DiseaseAgingDementia	2012	175
Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with Lamivudine Josée Gauthier, Eric Bourne, Michael W. Lutz, The Journal of Infectious Diseases Hbv ClearanceGenetic EpidemiologyHepatitis BImmunologyPathology	1999	123
Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine Marchelle I. Allen, Josée Gauthier, Manon Deslauriers, Journal of Clinical Microbiology	1999	120
The effect of <i>TOMM40</i> poly‐T length on gray matter volume and cognition in middle‐aged persons with <i>APOE</i><b>ɛ</b>3/<b>ɛ</b>3 genotype Sterling C. Johnson, Asenath La Rue, Bruce P. Hermann, Alzheimer s & Dementia	2011	114
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer, The Lancet Neurology Neurodegenerative DiseasesNeuropsychologyAlzheimer's DiseaseDementiaVascular Dementia	2021	108

Page 1